Kisspeptin treatment requires a 75-minute monthly infusion administered by a medical tech. This seems like a non-starter both from a lifestyle and cost standpoint.
Vyleesi (bremelanotide) is already approved by the FDA for HSDD in pre-menopausal women. It is administered by the patient as-needed using a subcutaneous injection in the leg or abdomen an hour before sexual activity. Given Vyleesi’s FDA approval and lower provider cost, it seems unlikely Kisspeptide would also get approved for HSDD by the FDA.
Vyleesi has been growing in prescriptions for a few years, but the makers, Palatin Technologies, are too small to advertise it and there is a real resistance from doctors to prescribe a drug that improves female sexual desire. Even in this day of generic Viagra, some things are considered taboo.